Press Release


October 12, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly
October 11, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Joins PhRMA to Continue Advancing Research and Innovation
October 4, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Announces Four Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Child Neurology Society Annual Meeting
September 18, 2017 - Basking Ridge, NJ (USA),
 
U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
September 15, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Announces Analysis of Managed Medicaid Data of Children with Cerebral Palsy at Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
September 14, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Announces Oral and Poster Presentations of abobotulinumtoxinA Data at the 2017 Annual Meeting of the American Academy of Cerebral Palsy and Developmental Medicine
June 30, 2017 - Basking Ridge, NJ (USA),
 
Ipsen announces Dysport® (abobotulinumtoxinA) co-promotion agreement with Saol Therapeutics to expand commercial reach in the United States
June 16, 2017 - Basking Ridge, NJ (USA),
 
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults
April 19, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the American Academy of Neurology
April 3, 2017 – Paris (France),
 
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
March 21, 2017 – Basking Ridge, NJ (USA),
 
Blazing New Trails™: Updates in the Care of Children with Cerebral Palsy
February 9, 2017 – Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 Annual Meeting of the Association of Academic Physiatrists
January 18, 2017 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium
January 9, 2017 – Paris, France,
 
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
October 26, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the 2016 Annual Meeting of the Child Neurology Society
October 19, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Data Presentations at the Annual Meeting of the American Academy of Physical Medicine & Rehabilitation
September 30, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Nine Poster Presentations at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium
September 21, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine
September 15, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. Announces Eight Presentations for Dysport® (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine
August 1, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older
June 4, 2016 - Basking Ridge, NJ (USA),
 
Endocrine Practice Publishes ELECT Phase III Trial Results in Adults with Carcinoid Syndrome
June 2, 2016 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentations of Somatuline® Depot (lanreotide) Injection in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
April 6, 2016 - Basking Ridge, NJ (USA),
 
Carcinoid Cancer Foundation and Self Care Catalysts Inc. to Provide a Free Digital Patient Support Application for Carcinoid and Neuroendocrine Tumor (NET) Patients, Sponsored in Part by Ipsen Biopharmaceuticals, Inc.
October 22, 2015 - Basking Ridge, NJ (USA),
 
Presentation of Results at the AACPDM Annual Meeting from a Phase III Trial Evaluating an Investigational Use of AbobotulinumtoxinA (Dysport®) in Children with Spastic Equinus Foot Deformity due to Cerebral Palsy
October 15, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Eight Studies of Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society (NANETS) Symposium
October 1, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Release of Additional Batch of Increlex® (mecasermin [rDNA origin] injection) in the U.S.
August 31, 2015 - Basking Ridge, NJ (USA),
 
Ipsen announces The Lancet Neurology publishes Dysport® Phase III registration trial results in adult patients with upper limb spasticity (ULS)
August 4, 2015 - Sacramento, CA (USA),
 
Ipsen Biopharmaceuticals, Inc. Receives Statewide Award for Achievements in Product Stewardship
July 16, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States
May 14, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Announces Data Presentations for Somatuline® Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
January 13, 2015 - Basking Ridge, NJ (USA),
 
Ipsen Biopharmaceuticals To Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline® Depot® (lanreotide), at Gastrointestinal Cancers Symposium
December 16, 2014 - Basking Ridge, NJ (USA),
 
Ipsen announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the treatment of gastroenteropancreatic neuroendocrine tumors

December 1, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients

November 24, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces IPSEN CARESTM, An Enhanced Patient Support Program

November 14, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Presents Dysport® (abobotulinumtoxinA) Data at American Academy of Physical Medicine and Rehabilitation Annual Assembly

November 6, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces FDA Approval of a New Delivery Device for Somatuline® Depot® (lanreotide) Injection

November 5, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology

September 18, 2014 - Basking Ridge, NJ (USA),

Baseline Data from a Phase III Trial in Pediatric Cerebral Palsy Presented at Meeting of the American Academy for Cerebral Palsy and Developmental Medicine

September 10, 2014 - Basking Ridge, NJ (USA),

Ipsen Biopharmaceuticals, Inc. Announces Key Medical and Commercial Hires

September 1, 2014 - Basking Ridge, NJ (USA),

Ipsen announces acceptance of filings for Somatuline® in the treatment of GEP-NETs in the US with priority review

August 26, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces Second Resupply of Increlex®(mecasermin [rDNA origin] Injection) in the U.S. in 2014

August 20, 2014 - Basking Ridge, NJ (USA),

Ipsen Appoints Cynthia Schwalm as President and CEO of Ipsen North America

July 16, 2014 - Basking Ridge, NJ (USA),

New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors

July 1, 2014 - Basking Ridge, NJ (USA),

Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

May 13, 2014 - Basking Ridge, NJ (USA),

Ipsen announces a step forward in the resupply of Increlex ® (mecasermin [rDNA origin] injection) in the U.S.

May 6, 2014 - Basking Ridge, NJ (USA),

Ipsen Announces Name Change for its Research and Development Affiliate in the U.S. From Biomeasure to Ipsen Bioscience, Inc.

17 January 2014 - Paris (France)

Ipsen announces at ASCO GI that ELECT® clinical trial of Somatuline® in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint

14 January 2014 - Paris (France)

Ipsen to set up its own US oncology team for Somatuline® Depot® (lanreotide) Injection in neuroendocrine tumors

26 September 2013 - Paris (France)

Ipsen to relocate US R&D activities to Cambridge, MA in 2014

15 July 2013 - Paris (France)

Ipsen announce a sponsored research agreement with Harvard Medical School to discover novel engineered botulinum toxins for serious neurologic diseases